EFFECTS OF ERYTHROPOIESIS-STIMULATING AGENTS ON OVERALL SURVIVAL OF IPSS LOW/INT-1 RISK TRANSFUSION INDEPENDENT MYELODYSPLASTIC SYNDROMEPATIENTS, A FISM STUDY

被引：0
|
作者：
Messa, E. [1 ]
Gioia, D. [2 ]
Masiera, E. [2 ]
Castiglione, A. [3 ]
Ceccarelli, M. [3 ]
Salvi, F. [4 ]
Danise, P. [5 ]
Sanna, A. [6 ]
Allione, B. [7 ]
Balleari, E. [8 ]
Poloni, A. [9 ]
Cametti, G. [1 ]
Ferrero, D. [7 ]
Tassara, R. [10 ]
Finelli, C. [11 ]
Bonferroni, M. [12 ]
Ciccone, G. [3 ]
Saglio, G. [13 ]
Levis, A. [2 ]
Santini, V. [6 ]
机构：
[1] ASLTO 5, Dept Internal Med, Turin, Italy
[2] Fdn Italiana Sindromi Mielodisplast Onlus, Hematol, Alessandria, Italy
[3] Azienda Osped Univ Citta Salute & Sci Torino, Piedmont Reference Ctr Canc Epidemiol & Prevent, Turin, Italy
[4] SS Antonio & Biagio Hosp, Hematol Dept, Alessandria, Italy
[5] ASL Salerno, Div Oncohematol Nocera Pagani, Salerno, Italy
[6] Azienda Osped Univ Careggi, Div Hematol, Florence, Italy
[7] Azienda Osped Univ Citta Salute & Sci Torino, Div Hematol, Turin, Italy
[8] IRCCS San Martino, Internal Med Dept, Genoa, Italy
[9] Osped Riuniti, Hematol Dept, Ancona, Italy
[10] ASL2 Savonese, Div Med & Hematol, Savona, Italy
[11] St Orsola Malpighi Univ Hosp, Inst Hematol L&A Seragnoli, Bologna, Italy
[12] Santa Croce & Carle Hosp, Div Hematol, Cuneo, Italy
[13] Mauriziano Hosp, Div Hematol, Turin, Italy
来源：
LEUKEMIA RESEARCH | 2017年 / 55卷
关键词：
D O I：
10.1016/S0145-2126(17)30206-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
93
引用
收藏
页码：S58 / S58
页数：1
相关论文
共 50 条
  • [31] Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
    Santini, Valeria
    Almeida, Antonio
    Giagounidis, Aristoteles
    Groepper, Stefanie
    Jonasova, Anna
    Vey, Norbert
    Mufti, Ghulam J.
    Buckstein, Rena
    Mittelman, Moshe
    Platzbecker, Uwe
    Shpilberg, Ofer
    Ram, Ron
    del Canizo, Consuelo
    Gattermann, Norbert
    Ozawa, Keiya
    Risueno, Alberto
    MacBeth, Kyle J.
    Zhong, Jianhua
    Seguy, Francis
    Hoenekopp, Albert
    Beach, C. L.
    Fenaux, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2988 - +
  • [32] Treatment-emergent adverse events (TEAEs) in lenalidomide (LEN)-treated Low-/Int-l-risk myelodysplastic syndromes (MDS) patients (pts) without del(5q) ineligible for or refractory to erythropoiesis-stimulating agents (ESAs).
    Almeida, Antonio Medina
    Fenaux, Pierre
    Garcia-Manero, Guillermo
    Giagounidis, Aristoteles
    Goldberg, Stuart
    Gropper, Stefanie
    Jonasova, Anna
    Mufti, Ghulam J.
    Sanz, Guillermo F.
    Vey, Norbert
    Castaneda, Carmen
    Zhong, Jianhua
    Beach, C. L.
    Santini, Valeria
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] TREATMENT-EMERGENT ADVERSE EVENTS IN LENALIDOMIDE-TREATED LOW/INT-1-RISK MYELODYSPLASTIC SYNDROMES PATIENTS WITHOUT DEL(5Q) INELIGIBLE FOR OR REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS
    Almeida, A.
    Fenaux, P.
    Garcia-Manero, G.
    Giagounidis, A.
    Goldberg, S.
    Groepper, S.
    Jonasova, A.
    Mufti, G. J.
    Sanz, G. F.
    Vey, N.
    Castaneda, C.
    Zhong, J.
    Beach, C.
    Santini, V.
    HAEMATOLOGICA, 2016, 101 : 502 - 502
  • [34] Observational Study of Magnetic Resonance Imaging Monitoring in Patients with Aplastic Anemia (AA) and Low or Int-1 Risk of Myelodysplastic Syndromes(MDS) Complicated with Iron Overload
    Du, Yali
    Han, Bing
    Long, Zhangbiao
    Chen, Miao
    Hou, Bo
    Feng, Feng
    Wang, Zhao
    BLOOD, 2016, 128 (22)
  • [35] Continuous Transfusion Independence With Imetelstat in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase III
    Platzbecker, Uwe
    Santini, Valeria
    Fenaux, Pierre
    Sekeres, Mikkael
    Savona, Michael
    Madanat, Yazan
    Diez-Campelo, Maria
    Valcarcel-Ferreiras, David
    Illmer, Thomas
    Jonasova, Anna
    Belohlavkova, Petra
    Sherman, Laurie
    Berry, Tymara
    Dougherty, Souria
    Shah, Sheetal
    Xia, Qi
    Peng, Lixian
    Sun, Libo
    Wang, Ying
    Huang, Fei
    Ikin, Annat
    Navada, Shyamala
    Feller, Faye
    Komrokji, Rami
    Zeidan, Amer
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S371 - S371
  • [36] Prognosis of Lower Risk Patients with Myelodysplastic Syndromes without Isolated Del(5q) after Failure of Erythropoiesis-Stimulating Agents. a Multicenter Study By the Hellenic MDS Study Group
    Galanopoulos, Athanasios G.
    Kontos, Christos K.
    Symeonidis, Argiris
    Kotsianidis, Ioannis
    Kourakli, Alexandra
    Pappa, Vassiliki
    Tsiambalis, Thomas
    Pouli, Anastasia
    Panayiotidis, Panayiotis
    Roussou, Paraskevi
    Karakatsanis, Stamatis
    Zafeiropoulou, Kalliopi
    Dimou, Maria
    Vassilakopoulos, Theodoros P.
    Vardi, Anna
    Tsokanas, Dimitrios
    Drakos, George
    Hatzimichael, Eleftheria
    Megalakaki, Aikaterini
    Repousis, Panagiotis
    Kotsopoulou, Maria
    Solomou, Elena E.
    Kaiafa, Georgia
    Papoutselis, Menelaos Konstantinos
    Sioni, Anastasia
    Charchalakis, Nikolaos
    Bouronikou, Eleni
    Vassilopoulos, George
    Lazaris, Vasileios
    Galanopoulos, Athanasios
    Diamantopoulos, Panagiotis Theodorou
    Kontopidou, Flora
    Topouzoglou, Zoi
    Kalyva, Stamatina
    Papadaki, Helen A.
    Hatzitolios, Apostolos
    Anagnostopoulos, Achilles
    Anagnostopoulos, Nikolaos
    Viniou, Nora-Athina
    BLOOD, 2017, 130
  • [37] Clinical Benefit of Luspatercept Treatment in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) in the COMMANDS Trial
    Zeidan, Amer M.
    Platzbecker, Uwe
    Della Porta, Matteo Giovanni
    Santini, Valeria
    Garcia-Manero, Guillermo
    Li, Jiahui
    Kreitz, Sandra
    Pozharskaya, Veronika
    Rose, Shelonitda
    Lai, Yinzhi
    Valcarcel, David
    Fenaux, Pierre
    Shortt, Jake
    Komrokji, Rami S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S387 - S388
  • [38] Identification of Poor Risk Patients in Low and Intermediate-1 (Int-1) IPSS MDS with the New Ipssr Index and Comparison with Other Prognostic Indexes. A Study by the Spanish Group of MDS (GESMD)
    Valcarcel, David
    Sanz, Guillermo
    Ortega, Margarita
    Nomdedeu, Benet
    Luno, Elisa
    Diez-Campelo, Maria
    Teresa Ardanaz, M.
    Pedro, Carmen
    Montoro, Julia
    Collado, Rosa
    Andreu, Rafa
    Marco, Victor
    Teresa Cedena, Maria
    de Paz, Raquel
    Tormo, Mar
    Xicoy, Blanca
    Ramos, Fernando
    Bargay, Joan
    Gonzalez, Bernardo
    Brunet, Salut
    Antonio Muaoz, Juan
    Gomez, Valle
    Bailen, Alicia
    Sanchez', Joaquin
    Vallespi, Teresa
    BLOOD, 2012, 120 (21)
  • [39] EFFECT OF BASELINE EPO AND PRIOR ERYTHROPOIESIS STIMULATING AGENTS ON RBC TRANSFUSION INDEPENDENCE IN LOW-/INT-1-RISK MDS WITH DEL5Q TREATED WITH LENALIDOMIDE: A RANDOMIZED PHASE 3 STUDY (MDS-004)
    Fenaux, P.
    Giagounidis, A.
    Selleslag, D.
    Knight, R.
    Fu, T.
    Hellstrom-Lindberg, E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 125 - 125
  • [40] Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κB Activation
    Randhawa, Jasleen K.
    Jabbar, Kausar Jabeen
    Kadia, Tapan
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Hearn, Katherine
    Bueso-Ramos, Carlos E.
    Garcia-Manero, Guillermo
    BLOOD, 2014, 124 (21)
12345